[Event Report] The Second Meeting of Working Group 5 on Vaccine Research and Development, “The Next Actions to Ensure the Development and Implementation of Immunization and Vaccine Policies” (January 17, 2022)
date : 1/28/2022
Tags: Vaccinations
![[Event Report] The Second Meeting of Working Group 5 on Vaccine Research and Development, “The Next Actions to Ensure the Development and Implementation of Immunization and Vaccine Policies” (January 17, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/20ffb867ca5b2b2f752fda033ff69c4a.jpg)
On January 17, 2022, Health and Global Policy Institute (HGPI) held the second meeting of Working Group 5 on vaccine research and development for “Next Actions for the Development and Implementation of Immunization and Vaccination Policies.”
This meeting was the second working group meeting on the R&D and production pipeline and, based on points raised at the previous meeting, examined the next steps needed to reinforce the vaccine R&D and production pipeline in the future. A multi-stakeholder group of experts in the field deepened discussions on the pharmaceutical regulation system for vaccines and the ability of the vaccine R&D and production systems, which are undergoing rapid investigation during the ongoing Coronavirus Disease 2019 (COVID-19) pandemic, to provide leadership and coordination.
To prevent the potential spread of COVID-19, this meeting was held online using a remote conferencing system.
■2021 Advisory Board Working Group 5 (Titles omitted; in alphabetical order by last name)
Members:
Ken J. Ishii (Professor, Division of Vaccine Science, Institute of Medical Science, The University of Tokyo/ Director, International Vaccine Design Center, Institute of Medical Science)
Masayuki Imagawa (Chief Executive, Japan Vaccine Industry Association/ Vice President & Head, Japan Vaccine Business Unit, Takeda Pharmaceutical Co., Ltd.)
Hiroshi Kasanuki (Specially Appointed Professor, Waseda University/ Advisor, Institute for Medical Regulatory Science, Waseda University)
Kengo Sonoda (General Manager, Development Department, R&D Division, KM Biologics Co., Ltd.)
Hideki Hasegawa (Director, Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases)
Yoshiharu Matsuura (Director, Center for Infectious Disease Education and Research (CiDER))
Shinji Matsumoto (Chair, Vaccines Working Team, EFPIA Japan)
Isao Miyairi (Professor, Faculty of Pediatrics, Hamamatsu University School of Medicine)
Yoshiaki Yamagishi (Associate Professor, Medical Center of Translational Research, Department of Medical Innovation, Osaka University)
Observer:
Yasuhiro Araki (Director, Office of Vaccine and Blood Products, Pharmaceuticals and Medical Devices Agency)
MC/Moderator
Takahiro Sakauchi (Associate, Health and Global Policy Institute)
Event Overview
Joji Sugawara (Manager, Health and Global Policy Institute)
■Related contents held as part of the project
– November 4, 2021 The First Meeting of Working Group 5 on Vaccine Research and Development, “Next Actions for the Development and Implementation of Immunization and Vaccination Policies”
日本語
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Establishing an Integrated Care System for Pain from the Perspectives of People with Lived Experience (March 29, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] Participation in an International Survey on Brain Health for Young People “The Next Generation (NextGen) Brain Health Research Program” (July 1, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Japanese Version Release] “Call for Actionable Steps in Response to the Rising Threat of Antimicrobial Resistance (AMR)” (July 3, 2024)
Featured Posts
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)
-
2024-07-17
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Towards Overcoming Kidney Disease: Strengthening Measures Against CKD” (June 7, 2024)
-
2024-07-18
[Registration Open] (Hybrid Format) Kidney Disease Control Promotion Project Public Symposium “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” (August 28, 2024)
-
2024-07-22
[HGPI Policy Column] No. 44 — From the Planetary Health Policy Project, Part 9 “Connecting Climate Minds: the Intersection of Climate Change and Mental Health”
-
2024-07-23
[Registration Open] (Webinar) HGPI Special Seminar “The Emerging Threat of Antifungal Resistance — Considering Infectious Diseases Caused by Mold and Measures to Combat Drug Resistance” (August 23, 2024)